Disc Medicine, Inc.
IRONNasdaq
$76.15
↑ +3.6%Jul 17 close · end-of-day
Price
1Y↑ +32.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.9B
Enterprise Value
$2.2B
P/E
—
P/S
—
P/B
4.3
EV/EBITDA
—
PEG
—
FCF Yield
-6.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$241.6M
Free Cash Flow (TTM)
-$201.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-35.1%
ROIC
—
Debt / Equity
0.0
Net Cash
$700.8M
Return 1Y
+31.8%
Company profile
Gemini Therapeutics, Inc. engages in developing therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) Its lead candidate is GEM103, a recombinant form of the human complement factor H protein. The company also develops GEM307 for treatment of systemic diseases.
- CEO
- Georges Gemayel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Massachusetts
- Website
- geminitherapeutics.com
Management & directors
- Quisel John DChief Executive Officer
- Yu Jonathan Yen-WenChief Operating Officer
- Khara RahulChief Legal Officer
- Franchi Jean M.Chief Financial Officer
- Savage William JacobChief Medical Officer
- Stephenson PamelaChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
IRON Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.65↑ +61.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$34.0M | -$30.9M | -$47.5M | -$91.1M | -$129.7M | -$236.0M |
| Net income | -$40.8M | -$36.0M | -$46.8M | -$76.4M | -$109.4M | -$212.2M |
| Diluted EPS | — | -$40.95 | -$45.05 | -$3.42 | -$3.96 | -$6.01 |
| Operating cash flow | -$32.7M | -$27.5M | -$42.3M | -$73.5M | -$93.9M | -$180.4M |
| Free cash flow | -$32.7M | -$27.6M | -$42.4M | -$73.6M | -$94.4M | -$181.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.9M | -$32.9M | -$34.5M | -$39.9M | -$61.4M | -$67.7M | -$67.0M | -$69.5M |
| Net income | -$26.4M | -$26.6M | -$29.5M | -$34.1M | -$55.2M | -$62.3M | -$60.5M | -$63.5M |
| Diluted EPS | -$1.03 | -$0.89 | -$0.95 | -$1.02 | -$1.58 | -$1.77 | -$1.64 | -$1.65 |
| Operating cash flow | -$15.4M | -$17.4M | -$27.6M | -$41.4M | -$47.9M | -$47.8M | -$43.3M | -$62.2M |
| Free cash flow | -$15.4M | -$17.4M | -$28.0M | -$42.2M | -$48.0M | -$47.8M | -$43.3M | -$62.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Quisel John D· Chief Executive Officer | Sale | 16,896 | $74.95 | $1.3M | filing |
| 2026-07-13 | Quisel John D· Chief Executive Officer | Sale | 9,704 | $74.27 | $720,744.22 | filing |
| 2026-07-13 | Quisel John D· Chief Executive Officer | Sale | 6,400 | $76.05 | $486,732.80 | filing |
| 2026-07-13 | Quisel John D· Chief Executive Officer | Option exercise | 25,584 | $9.86 | $252,258.24 | filing |
| 2026-07-13 | Quisel John D· Chief Executive Officer | Option exercise | 7,416 | $13.50 | $100,116.00 | filing |
| 2026-07-07 | Yu Jonathan Yen-Wen· Chief Operating Officer | Sale | 100 | $82.50 | $8,250.00 | filing |
| 2026-07-07 | Yu Jonathan Yen-Wen· Chief Operating Officer | Option exercise | 100 | $13.50 | $1,350.00 | filing |
| 2026-06-29 | Khara Rahul· Chief Legal Officer | Sale | 1,649 | $75.00 | $123,675.00 | filing |
| 2026-06-29 | Khara Rahul· Chief Legal Officer | Option exercise | 1,649 | $14.69 | $24,223.81 | filing |
| 2026-06-26 | Khara Rahul· Chief Legal Officer | Sale | 851 | $75.00 | $63,825.00 | filing |
| 2026-06-26 | Yu Jonathan Yen-Wen· Chief Operating Officer | Sale | 300 | $72.50 | $21,750.00 | filing |
| 2026-06-26 | Khara Rahul· Chief Legal Officer | Option exercise | 851 | $14.69 | $12,501.19 | filing |
| 2026-06-26 | Yu Jonathan Yen-Wen· Chief Operating Officer | Option exercise | 300 | $13.50 | $4,050.00 | filing |
| 2026-06-22 | Yu Jonathan Yen-Wen· Chief Operating Officer | Sale | 9,700 | $72.66 | $704,795.21 | filing |
| 2026-06-22 | Yu Jonathan Yen-Wen· Chief Operating Officer | Option exercise | 9,700 | $13.50 | $130,950.00 | filing |
| 2026-06-18 | Quisel John D· Chief Executive Officer | Sale | 22,927 | $69.92 | $1.6M | filing |
| 2026-06-18 | Quisel John D· Chief Executive Officer | Sale | 9,522 | $70.70 | $673,205.40 | filing |
| 2026-06-18 | Khara Rahul· Chief Legal Officer | Sale | 5,400 | $69.94 | $377,688.42 | filing |
| 2026-06-18 | Quisel John D· Chief Executive Officer | Option exercise | 34,000 | $9.86 | $335,240.00 | filing |
| 2026-06-18 | Khara Rahul· Chief Legal Officer | Sale | 1,600 | $70.73 | $113,161.12 | filing |
| 2026-06-18 | Quisel John D· Chief Executive Officer | Sale | 1,551 | $71.61 | $111,071.14 | filing |
| 2026-06-18 | Khara Rahul· Chief Legal Officer | Option exercise | 7,500 | $14.69 | $110,175.00 | filing |
| 2026-06-18 | Khara Rahul· Chief Legal Officer | Sale | 500 | $71.62 | $35,811.00 | filing |
| 2026-06-16 | Yu Jonathan Yen-Wen· Chief Operating Officer | Sale | 11,651 | $68.76 | $801,101.79 | filing |
| 2026-06-16 | Yu Jonathan Yen-Wen· Chief Operating Officer | Sale | 6,961 | $69.92 | $486,699.20 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.